Revealing novel mode of action for osteoporosis drug
Raloxifene is a US Food and Drug Administration-approved treatment for decreasing fracture risk in osteoporosis. While raloxifene is as effective at reducing fracture risk as other current treatments, this works only partially by suppressing bone loss. X-ray studies revealed an additional mechanism underlying raloxifene action, providing an explanation for how this drug can achieve equivalent clinical benefit.
Source: ScienceDaily Headlines - Category: Science Source Type: news
More News: Evista | Food and Drug Administration (FDA) | Orthopaedics | Osteoporosis | Science | Study